|
1
|
Senoo S, Ninomiya K, Hotta K and Kiura K:
Recent treatment strategy for advanced squamous cell carcinoma of
the lung in Japan. Int J Clin Oncol. 24:461–67. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wu D, Huo C, Jiang S, Huang Y, Fang X, Liu
J, Yang M, Ren J, Xu B and Liu Y: Exostosin1 as a novel prognostic
and predictive biomarker for squamous cell lung carcinoma: A study
based on bioinformatics analysis. Cancer Med. 10:2787–2801.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Rafei H, El-Bahesh E, Finianos A,
Nassereddine S and Tabbara I: Immune-based therapies for non-small
cell lung cancer. Anticancer Res. 37:377–387. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Goldstraw P, Ball D, Jett JR, Chevalier
TL, Lim E and Nicholson AG: Non-small-cell lung cancer. Lancet.
378:1727–1740. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sholl LM: Biomarkers in lung
adenocarcinoma: A decade of progress. Arch Pathol Lab Med.
139:469–480. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and radical disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sun Y, Yin X, Wen MM, Zhang J, Wang XJ,
Xia JH, Zhang YN, Zhang ZP and Li XF: EGFR mutations subset in
Chinese lung squamous cell carcinoma patients. Mol Med Rep.
17:7575–7584. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cancer Genome Atlas Research Network.
Comprehensive genomic characterization of squamous cell lung
carcinoma. Nature. 489:519–525. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
West H, McCleod M, Hussein M, Morabito A,
Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, et
al: Atezolizumab in combination with carboplatin plus
nab-paclitaxel chemotherapy compared with chemotherapy alone as
first-line treatment for metastatic non-squamous non-small-cell
lung cancer (Impower130): A multicentre, randomised, open-label,
phase 3 trial. Lancet Oncol. 20:924–937. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Langer CJ, Gadgeel SM, Borghaei H,
Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins
RG, Stevenson JP, Jalal SI, et al: Carboplatin and pemetrexed with
or without pembrolizumab for advanced, non-squamous non-small-cell
lung cancer: A randomised, phase 2 cohort of the open-label
KEYNOTE-021 study. Lancet Oncol. 17:1497–1508. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Reck M, Shankar G, Lee A, Coleman S,
McCleland M, Papadimitrakopoulou VA, Socinski MA and Sandler A:
Atezolizumab in combination with bevacizumab, paclitaxel and
carboplatin for the first-line treatment of patients with
metastatic non-squamous non-small cell lung cancer, including
patients with EGFR mutations. Expert Rev Respir Med. 14:125–136.
2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bonda WLM, Iochmann S, Magnen M, Courty Y
and Reverdiau P: Kallikrein-related peptidases in lung diseases.
Biol Chem. 399:959–971. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lenga Ma Bonda W, Lavergne M, Vasseur V,
Brisson L, Roger S, Legras A, Guillon A, Guyétant S, Hiemstra PS,
et al: Kallikrein-related peptidase 5 contributes to the remodeling
and repair of bronchial epithelium. FASEB J.
35(e21838)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chou RH, Lin SC, Wen HC, Wu CW and Chang
WS: Epigenetic activation of human kallikrein 13 enhances
malignancy of lung adenocarcinoma by promoting N-cadherin
expression and laminin degradation. Biochem Biophys Res Commun.
409:442–447. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tokas T, Avgeris M, Alamanis C, Scorilas
A, Stravodimos KG and Constantinides CA: Downregulated KLK13
expression in bladder cancer highlights tumor aggressiveness and
unfavorable patients’ prognosis. J Cancer Res Clin Oncol.
143:521–532. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ishige S, Kasamatsu A, Ogoshi K, Saito Y,
Usukura K, Yokoe H, Kouzu Y, Koike H, Sakamoto Y, Ogawara K, et al:
Decreased expression of kallikrein-related peptidase 13: Possible
contribution to metastasis of human oral cancer. Mol Carcinog.
53:557–565. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Chang A, Yousef GM, Scorilas A, Grass L,
Sismondi P, Ponzone R and Diamandis EP: Human kallikrein gene 13
(KLK13) expression by quantitative RT-PCR: An independent indicator
of favourable prognosis in breast cancer. Br J Cancer.
86:1457–1464. 2002.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Björkman K, Mustonen H, Kaprio T, Haglund
C and Böckelman C: Mucin 16 and Kallikrein 13 as potential
prognostic factors in colon cancer: Results of an oncological
92-multiplex immunoassay. Tumour Biol.
41(1010428319860728)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Nohara K, Yamada K, Yamada L, Hagiwara T,
Igari T, Yokoi C, Soma D, Yamashita S, Dohi T and Kawamura YI:
Expression of kallikrein-related peptidase 13 is associated with
poor prognosis in esophageal squamous cell carcinoma. Gen Thorac
Cardiovasc Surg. 66:351–357. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Brierley JD, Gospodarowicz MK and
Wittekind C: UICC International Union Against Cancer (eds). TNM
classification of malignant tumours. 8th edition. WileyBlackwell,
NY, 2017.
|
|
21
|
Gueugnon F, Barascu A, Mavridis K,
Petit-Courty A, Marchand-Adam S, Gissot V, Scorilas A, Guyetant S
and Courty Y: Kallikrein-related peptidase 13: An independent
indicator of favorable prognosis for patients with nonsmall cell
lung cancer. Tumour Biol. 36:4979–4986. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Miyagi J, Tsuhako K, Kinjo T, Iwamasa T
and Hirayasu T: Recent striking in histological differentiation and
rate of human papillomavirus infection in squamous cell carcinoma
of the lung in Okinawa, a subtropical island in southern Japan. J
Clin Pathol. 53:676–684. 2000.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Affandi KA, Tizen NMS, Mustangin M and Zin
RRMRM: P40 immunohistochemistry is an excellent marker in primary
lung squamous cell carcinoma. J Pathol Transl Med. 52:283–289.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Araki K, Adachi Y, Metsugi H and Tokushima
T: Prognostic implication of lymphatic vessel invasion in stage IB
(pT2aN0M0) non-small cell lung cancer. Gen Thorac Cardiovasc Surg.
59:605–608. 2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wang J, Wang B, Zhao W, Guo Y, Chen H, Chu
H, Liang X and Bi J: Clinical significance and role of lymphatic
vessel invasion as a major prognostic implication in non-small cell
lung cancer: A meta-analysis. PLoS One. 7(e52704)2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Planque C, Bléchet C, Ayadi-Kaddour A,
Heuzé-Vourc’h N, Dumont P, Guyétant S, Diamandis EP, El Mezni F and
Courty Y: Quantitative RT-PCR analysis and immunohistochemical
localization of the kallikrein-related peptidases 13 and 14 in
lung. Biol Chem. 389:781–786. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 world health organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
An N, Leng X, Wang X, Sun Y and Chen Z:
Survival comparison of three histological subtypes of lung squamous
cell carcinoma: A population-based propensity score matching
analysis. Lung Cancer. 142:13–19. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chen R, Ding Z, Zhu L, Lu S and Yu Y:
Correlation of clinicopathologic features and lung squamous cell
carcinoma subtypes according to the 2015 WHO. classification.
43:2308–2314. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lin Q, Mao W, Wu Q, He X, Li S, Fan Y,
Chen J, Feng T and Cao X: Downregulation of KLK13 promotes the
invasiveness and metastasis of oesophageal squamous cell carcinoma.
Biomed Pharmacother. 96:1008–1015. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hural JA, Friedman RS, McNabb A, Steen SS,
Henderson RA and Kalos M: Identification of naturally processed CD4
T cell epitopes from the prostate-specific antigen kallikrein 4
using peptide-based in vitro stimulation. J Immunol. 169:557–565.
2002.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Borgoño CA and Diamandis EP: The emerging
roles of human tissue kallikreins in cancer. Nat Rev Cancer.
4:876–890. 2004.PubMed/NCBI View
Article : Google Scholar
|
